The natural history and ocular complications of sickle cell retinopathy are extensively described,l-4 but little attention has been focussed on the frequency or causes of visual loss associated with this condition. The pre sent study describes visual loss in patients with untreated sickle cell retinopathy and dis cusses the causes of visual morbidity.
Materials and Methods
Over 3000 patients have attended the sickle cell clinic of the University Hospital of the West Indies or a group of periheral sickle cell clinics operated by staff of the Medical Research Council Laboratories. This repre sents approximately one third of all Jamaicans with sickling haemog lobinopathies.
The study group consisted of all those patients with SS or SC disease, aged 15 years and over who underwent ophthalmic screen ing on at least two occasions separated by 3 months or more during the 10 year period 1st October 1976 to 30th September 1986. Cataracts preventing fundoscopy caused exclusion of 16 eyes. Dense vitreous haemor rhages prevented fundoscopy at the start of the study in 14 eyes but these eyes were included after spontaneous resolution of the haemorrhage. No eyes had received treat ment prior to entry into the study. The final study group included 342 patients (120 SS, 222 SC) aged 15-60 years at enrolmenL The age and sex distribution of patients is sum marised in Table 1 . The average duration of follow-up of patients was 6.9 years (Fig 1) .
Assessment included visual symptoms, corrected visual acuity, slit lamp biomicros copy and intraocular pressure. Direct and indirect ophthalmoscopy were carried out after mydriasis. Red free and colour photo graphy and fluorescein angiography were performed where appropriate.
'Moderate' visual loss was defined as best corrected visual acuity of 6/18 -6/60 and 'se vere' visual loss as best corrected visual acuity <6/60, on at least two occasions sepa rated by at least 3 months. Those eyes show ing 'severe' visual loss after a preceding episode of 'moderate' visual loss (e.g. vitre- ous haemorrhages, tractional retinal detach ment) were counted as 'severe'. If any eye developed proliferative changes after a pre ceding period of non-proliferative -retinopathy, the eye was classified as 'pro liferative' and follow-up time was measured from the time of onset of proliferative dis ease.
A randomised controlled trial of Xenon feeder coagulation of proliferative sickle retinopathy (PSR5.6 conducted between 1978 and 1980 resulted in the treatment of 53 eyes of 78 patients. A randomised controlled trial of Argon scatter photocoagulation conducted since 1982 has resulted in the treatment on 61 eyes of 67 patients. This report describes vis ual loss in the control eyes of these trials and in both eyes of all other patients where fun doscopy was possible.
Results
Visual loss (V.A.� 6/18) occurred in 72 eyes during the study period.
In 52 (10%) eyes of 49 (15%) patients, this was attributable to sickle cell retinopathy, being associated with proliferative changes in 45 eyes and non-proliferative changes in 7 eyes. Visual loss was 'severe' in 27/52 (52%) of eyes involved. The prevalence of visual loss was 45/134 (34%) among eyes affected by PSR which was significantly greater (X2 = 114. 2, p<O.OOl) than among the 7/420 (2%) eyes with non-proliferative disease. The inci dence of visual loss was 31 per 1000 eye-years of observation among eyes affected by PSR compared to 1.4 per 1000 eye-years among eyes with non-proliferative changes (X2 = 110.2, p<O.OOl) giving a relative risk of 23 (95% confidence interval = 8-66).
The commonest causes of visual loss among eyes affected by PSR were vitreous haemorrhage and traction retinal detachment (Table II) . Analysis of 16 eyes with vitreous haemorrhages examined within two weeks of onset of symptoms and observed over one year indicated that first symptomatic haemorrhages were associated with transient « 3 months) and generally moderate visual loss whereas subsequent symptomatic haemorrhages generally caused prolonged (> 3 months) and severe visual loss (Table  III) . The commonest cause of visual loss among eyes without proliferative change was angioid streaks and disciform degeneration (Table IV) . In 20 eyes, visual loss was not attributable to sickle cell disease but to cataract (8 eyes), glaucoma (5 eyes), uveitis (5 eyes), myopia and trauma (1 eye each).
Discussion
There have been few assessments on the pre valence of visual loss in patients with sickle cell disease. An earlier study3 described severe visual loss in 12% of eyes with PSR over an average follow-up of 4 years but since eyes severely affected by PSR were enrolled in a trial of Xenon arc photocoagulation,? this may have underestimated the prevalence of visual loss among untreated patients. The present study observed severe visual loss in 17% of PSR af£ected eyes over a mean fol low-up period of 6.9 years. demonstrated a higher prevalence of PSR in the SC patients (32%) compared to SS patients (3% ).2,3 Screening of asymptomatic patients is biased towards SC patients. This is reflected in the study group described, by the Earlier studies on non-selected patients Visual loss in sickle cell retinopathy is prin cipally determined by PSR which predisposes to vitreous haemorrhage, vitreous traction, retinal detachment, and epiretinal membrane formation. 8 Auto-infarction of PSR may reduce the chance of visual loss but the pre sent study indicates that a considerable risk of visual loss remains. Vitreous haemorrhage was the most frequent cause of both 'moder ate' and 'severe' visual loss.
Risk factors for vitreous haemorrhage have been identified as the SC genotype, pre sence of previous vitreous haemorrhage, and PSR involving more than 60° of the retinal circumference.6 Iron and blood products from previous haemorrhage may accelerate vitreous degeneration, causing further trac tion and predisposing to further more persis tent, vitreous haemorrhage and/or a trac tional detachment.
Tractional retinal detachment (Fig 2) results from elevation of the retina by adhe rent vitreous bands, and the majority of such detachments (85%) occurred in eyes with pre-existing vitreous haemorrhage. Involve ment of the posterior pole usually results in severe visual loss difficult to treat by conven tional surgery9 although occasionally amena ble to therapy with the Neodymium:YAG laser. Rhegmatogenous retinal detachment (Fig 3) is uncommon in sickle cell retinopathy but may result from traction on thin atrophic retina.
Epiretinal membranes may be responsible for moderate visual loss in sickle cell disease, and occasionally a localised associated trac tional retinal detachment (Fig 4) may result in severe visual loss. Risk factors for ERM formation including the presence and extent of PSR involvement, pre-existing vitreous haemorrhage, and non-treatment of PSR. 8 Angioid streaks in sickle cell disease are usually of the mild peripapillary type and rarely cause visual loss, 10 although severe vis ual loss from untreatable disciform macular degeneration (Fig 5) secondary to a pre sumed sub retinal neovascular membrane (SRNVM) occurred in 4 eyes.
Posterior pole vaso-occlusion is a rare cause of prolonged visual loss, although cent ral retinal artery occlusion,2.11 branch arterio lar occlusion 12 and macular infarction 13 have all been reported. Sickling maculopathy results from discrete occlusions and remodel ling of the capillary network causing pathological avascular zones and enlarge ment of the foveal avascular zonel4-16 (Fig 6) .
The visual loss in sickle cell retinopathy affects a relatively young group of patients and is largely associated with proliferative disease. Using our incidence figures in con junction with prevalence rates of PSR in SS and SC disease of 3% and 32% respectively, it can be estimated that 73%. of visual loss in sickle cell retinopathy is attributable to pro liferative disease (95% confidence interval = 47-89). Avoidance of such visual loss must therefore depend on the early detection and effective treatment of proliferative disease. 
